Diagnosis and management of pulmonary arterial hypertension: Implications for respiratory care

Respiratory Care

Volumn 51, Issue 4, 2006, Pages 368-381

  Levine, Deborah Jo ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cor pulmonale; Pulmonary arterial hypertension; Pulmonary hypertension; Pulmonary vascular disease; Right heart failure

Indexed keywords

ADENOSINE; AMBRISENTAN; AMINOREX; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DEXFENFLURAMINE; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FENFLURAMINE; GLYCOSIDE; ILOPROST; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN;

CARDIOPULMONARY EXERCISE TEST; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; COR PULMONALE; COUGHING; DIARRHEA; DRUG INDUCED HEADACHE; ELECTROCARDIOGRAM; FLUSHING; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOXEMIA; LABORATORY TEST; LEG PAIN; LIVER DISEASE; LUNG BLOOD VESSEL; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; LUNG VENTILATION PERFUSION RATIO; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PULMONARY HYPERTENSION; RESPIRATORY CARE; RESPIRATORY THERAPIST; RISK FACTOR; SICKLE CELL ANEMIA; SIDE EFFECT; SLEEP; VOMITING; ARTICLE; ARTIFICIAL VENTILATION; CLASSIFICATION; DIAGNOSTIC PROCEDURE; METHODOLOGY; UNITED STATES;

DIAGNOSTIC TECHNIQUES AND PROCEDURES; HUMANS; HYPERTENSION, PULMONARY; RESPIRATORY THERAPY; RISK FACTORS; UNITED STATES;

EID: 33748337526     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361(9368):1533-1544.
2. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107(2):216-223.
3. Kim NH. Diagnosis and evaluation of the patient with pulmonary hypertension. Cardiol Clin 2004;22(3):367-373.
4. Bristow MR, Zisman LS, Lowes BD, Abraham WT, Badesch DB, Groves BM, et al. The pressure-overloaded right ventricle in pulmonary hypertension. Chest 1998;114(1 Suppl):101S-106S.
5. Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits (editorial). Circulation 2005;111(5):534-538.
6. Wagenvort CA, Mulder PG. Thrombotic lesions in primary plexogenic arteriopathy: similar pathogenesis or complication? Chest 1993;103(3):844-849.
7. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;(12 Suppl S):13S-24S.
8. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327(2):70-75.
9. Giaid A, Seleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333(4):214-221.
10. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159(6):1925-1932.
11. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70(4):580-587.
12. Wagenwoort C. Wagenwoort N. Primary pulmonary hypertension: a pathological study of the lung vessels in 156 diagnosed cases. Circulation 1970;42:1163-1184.
13. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302.
14. Rubin L. ACCP Consensus statement: primary pulmonary hypertension. Chest 1993;104(1):236-250.
15. Rubin LJ; American College of Chest Physicians. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(Suppl 1):7s-10s.
16. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336(2):111-117.
17. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70(4):580-587.
18. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, et al. Clinical and molecular geneticfeaturesof pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345(5):325-334.
19. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PHH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67(3):737-744.
20. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335(9):609-616.
21. Fishman AP. Aminorex to fen/phen: an epidemic foretold. Circulation 1999;99(1):156-161.
22. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997;3(5):494-500.